RxDoctor Payments DataLook up a doctor →

Gary Alexander, MD

Pulmonary Disease · Layton, UTNPI 1265418024

Payments from drug & device makers

$19,736in general payments, 2019–2025

Across 527 payments — averaging $37.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$10K
  • AstraZeneca$2K
  • Inspire Medical Systems, Inc.$1K
  • Harmony Biosciences LLC$546
  • Mylan Specialty L.p.$523
  • Grifols USA, LLC$422
  • plus $5K from 47 others
$1,023in research payments, 2019–2025

Across 6 payments — averaging $170.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$19,736 in reported general payments places this provider in the 75th percentile of 101 pulmonary disease providers in Utah.

See all pulmonary disease providers in Utah

Medicare billing

Part B allowed, 2024
$152,443
Medicare patients
619
Services billed
1,216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Layton

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →